Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161582 | 1.00 | MME (0.66) | MMEHRH4 | |
| SCHEMBL7315829 | 1.00 | MME (0.66) | MMEHRH4 | |
| SCHEMBL6161590 | 1.00 | MME (0.66) | MMEHRH4 | |
| SCHEMBL6574501 | 1.00 | MME (0.66) | MMEHRH4 | |
| SCHEMBL6161839 | 0.92 | MME (0.56) | MMEHRH4 | |
| SCHEMBL6161489 | 0.92 | MME (0.56) | MMEHRH4 | |
| SCHEMBL6162737 | 0.90 | MME (0.53) | MME | |
| SCHEMBL6162747 | 0.90 | MME (0.53) | MME | |
| SCHEMBL6161391 | 0.89 | MME (0.53) | MMEHRH4 | |
| SCHEMBL6161384 | 0.89 | MME (0.53) | MMEHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-5994539-A | Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory activity, useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.P.A. (IT) | 1999-11-30 | — | — | US | claimed |
| US-20230340528-A1 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | ASKLEPIOS BIOPHARMACEUTICAL INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4192580-A2 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | Asklepios Biopharmaceutical, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022031914-A2 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-2258447-A2 | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | Pfizer Italia S.r.l. (IT) | 2010-12-08 | — | — | EP | disclosed |
| US-20090005327-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC IN SUFFICIENCY AND HEART FAILURE THERAPY | PFIZER ITALIA S.R.L. (IT) | 2009-01-01 | — | — | US | disclosed |
| US-7439267-B2 | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | PFIZER ITALIA S.R.L. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-20060205814-A1 | Administering mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester; cardiovascular disorders; administered along with ACE-, NEP-, or phosphodiesterase inhibitors; diuretics, positive inotropic drugs, vasodilators, beta-blockers, digitalis glycosides | PHARMACIA ITALIA S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-0877740-B1 | THIOL DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY | ZAMBON SPA (IT) | 2005-03-30 | — | — | EP | disclosed |
| EP-1474405-A2 | PROCESS FOR THE PREPARATION OF 4-HETERO-SUBSTITUTED PHENYLALANINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040077723-A1 | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-22 | — | — | US | disclosed |
| EP-1365841-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC INSUFFICIENCY AND HEART FAILURE THERAPY | Pharmacia Italia S.p.A. (IT) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003068725-A2 | PROCESS FOR THE PREPARATION OF 4-HETERO-SUBSTITUTED PHENYLALANINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002058793-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC INSUFFICIENCY AND HEART FAILURE THERAPY | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-01 | — | — | WO | disclosed |
| US-5994539-A | Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory activity, useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.P.A. (IT) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | MME 76/4885HRH4 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.